237 related articles for article (PubMed ID: 20866165)
1. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
[TBL] [Abstract][Full Text] [Related]
2. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
[TBL] [Abstract][Full Text] [Related]
3. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
[TBL] [Abstract][Full Text] [Related]
5. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
6. Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
O'Lone EL; Hodson EM; Nistor I; Bolignano D; Webster AC; Craig JC
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD007857. PubMed ID: 30790278
[TBL] [Abstract][Full Text] [Related]
7. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
8. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care.
Wetmore JB; Tzivelekis S; Collins AJ; Solid CA
BMC Nephrol; 2016 May; 17(1):53. PubMed ID: 27228981
[TBL] [Abstract][Full Text] [Related]
9. Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
Albaramki J; Hodson EM; Craig JC; Webster AC
Cochrane Database Syst Rev; 2012 Jan; 1():CD007857. PubMed ID: 22258974
[TBL] [Abstract][Full Text] [Related]
10. Economic considerations in a changing anemia environment.
Pizzi LT
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
[TBL] [Abstract][Full Text] [Related]
11. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
Winkelmayer WC; Mitani AA; Goldstein BA; Brookhart MA; Chertow GM
JAMA Intern Med; 2014 May; 174(5):699-707. PubMed ID: 24589911
[TBL] [Abstract][Full Text] [Related]
12. Transfusion burden among patients with chronic kidney disease and anemia.
Lawler EV; Bradbury BD; Fonda JR; Gaziano JM; Gagnon DR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):667-72. PubMed ID: 20299366
[TBL] [Abstract][Full Text] [Related]
13. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective.
Gauthier-Loiselle M; Michalopoulos SN; Cloutier M; Serra E; Bungay R; Szabo E; Guérin A
J Manag Care Spec Pharm; 2021 Dec; 27(12):1703-1713. PubMed ID: 34818094
[No Abstract] [Full Text] [Related]
14. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing.
Karaboyas A; Zee J; Morgenstern H; Nolen JG; Hakim R; Kalantar-Zadeh K; Zager P; Pisoni RL; Port FK; Robinson BM
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1814-21. PubMed ID: 26286925
[TBL] [Abstract][Full Text] [Related]
16. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
18. Comparative mortality risk of anemia management practices in incident hemodialysis patients.
Brookhart MA; Schneeweiss S; Avorn J; Bradbury BD; Liu J; Winkelmayer WC
JAMA; 2010 Mar; 303(9):857-64. PubMed ID: 20197532
[TBL] [Abstract][Full Text] [Related]
19. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015).
Park H; Liu X; Henry L; Harman J; Ross EA
BMC Nephrol; 2018 Nov; 19(1):318. PubMed ID: 30413150
[TBL] [Abstract][Full Text] [Related]
20. Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.
Thamer M; Zhang Y; Kshirsagar O; Cotter DJ; Kaufman JS
Am J Kidney Dis; 2014 Nov; 64(5):706-13. PubMed ID: 25011692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
